---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-23-000024"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T14:52:38.228351+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific Q1 beat: sales $3.39B (+14% organic), adj EPS $0.47, guides up

## Summary
- Q1 net sales $3.389B (+14% organic vs guide 6-8%), GAAP EPS $0.21, adjusted EPS $0.47 vs guide $0.42-0.44.
- Cardiovascular +15.9% operational; MedSurg +13.4%; U.S. +12.7%, EMEA +20% operational.
- FY23 organic sales growth guidance raised to 8-10%; adjusted EPS forecast $1.90-$1.96.
- Q2 guidance: organic sales +7-9%; adjusted EPS $0.48-$0.50.
- Closed acquisitions of Apollo Endosurgery and majority stake in Acotec; FDA clearance for LithoVue Elite.

## SEC filing metadata
- accession: 0000885725-23-000024
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572523000024/0000885725-23-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572523000024/bsx-20230426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-23-000024
- JSON: https://secwatch.observer/filing/0000885725-23-000024.json
- Plain text: https://secwatch.observer/filing/0000885725-23-000024.txt

## Key facts
- Earnings Releases
  BOSTON SCIENTIFIC CORP reported first quarter ended March 31, 2023 results: revenue $3.389 billion, net income $300 million or $0.21 per share (EPS), compared to $97 million or $0.07 per share a year ago, and achieved adjusted EPS, EPS $0.21 per share.
  - Period: first quarter ended March 31, 2023
  - Revenue: $3.389 billion
  - Net income: $300 million or $0.21 per share (EPS), compared to $97 million or $0.07 per share a year ago, and achieved adjusted EPS
  - EPS: $0.21 per share
  - Result: reported results
  source text: RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2023 Marlborough, Mass. (April 26, 2023) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational 1 basis and 14.0 percent on an organic 2 basis, all compared to the
  evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572523000024/0000885725-23-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.